J A Desmeules

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. doi request reprint Psychological distress in fibromyalgia patients: a role for catechol-O-methyl-transferase Val158met polymorphism
    Jules Desmeules
    Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva University, Switzerland
    Health Psychol 31:242-9. 2012
  2. ncbi request reprint Advances with analgesics and NSAIDs for the treatment of spinal disorders
    J A Desmeules
    Division of Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Geneva University Hospital, Switzerland
    Best Pract Res Clin Rheumatol 16:105-21. 2002
  3. ncbi request reprint Neurophysiologic evidence for a central sensitization in patients with fibromyalgia
    J A Desmeules
    Geneva University Hospital, Geneva, Switzerland
    Arthritis Rheum 48:1420-9. 2003
  4. ncbi request reprint Clinical pharmacology and rationale of analgesic combinations
    J Desmeules
    Division of Clinical Pharmacology and Toxicology, Clinical Pharmacology and Multidisciplinary Pain Centre, University Hospital, Geneva, Switzerland
    Eur J Anaesthesiol Suppl 28:7-11. 2003
  5. pmc Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety
    C F Samer
    Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Department of Anaesthesiology, Pharmacology and Intensive Care, Geneva University Hospitals, Geneva, Switzerland
    Br J Pharmacol 160:919-30. 2010
  6. pmc The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone
    C F Samer
    Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Department of Anaesthesiology, Pharmacology and Intensive Care, Geneva University Hospitals, Switzerland
    Br J Pharmacol 160:907-18. 2010
  7. doi request reprint Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital
    L Gschwind
    Division of Clinical Pharmacology and Toxicology, University Hospitals of Geneva, Rue Gabrielle Perret Gentil 4, 1211 Geneva 14, Switzerland
    Eur J Clin Pharmacol 69:617-27. 2013
  8. pmc Applications of CYP450 testing in the clinical setting
    C F Samer
    Clinical Pharmacology and Toxicology, Geneva University Hospitals, Rue Gabrielle Perret Gentil 4, 1211, Geneva, Switzerland
    Mol Diagn Ther 17:165-84. 2013
  9. ncbi request reprint Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients
    Y Daali
    Clinical Pharmacology and Toxicology, Geneva University Hospitals, CH 1211 Geneva 14, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 861:56-63. 2008
  10. ncbi request reprint Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability
    V Ancrenaz
    Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, rue Gabrielle Perret Gentil, 1211 Geneva 14, Switzerland
    Curr Drug Metab 11:667-77. 2010

Collaborators

Detail Information

Publications10

  1. doi request reprint Psychological distress in fibromyalgia patients: a role for catechol-O-methyl-transferase Val158met polymorphism
    Jules Desmeules
    Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva University, Switzerland
    Health Psychol 31:242-9. 2012
    ..Among genetic and environmental hypotheses, a role was suggested for catechol-O-methyl-transferase (COMT), a modulator in the metabolism of monoaminergic neurotransmitters...
  2. ncbi request reprint Advances with analgesics and NSAIDs for the treatment of spinal disorders
    J A Desmeules
    Division of Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Geneva University Hospital, Switzerland
    Best Pract Res Clin Rheumatol 16:105-21. 2002
    ....
  3. ncbi request reprint Neurophysiologic evidence for a central sensitization in patients with fibromyalgia
    J A Desmeules
    Geneva University Hospital, Geneva, Switzerland
    Arthritis Rheum 48:1420-9. 2003
    ....
  4. ncbi request reprint Clinical pharmacology and rationale of analgesic combinations
    J Desmeules
    Division of Clinical Pharmacology and Toxicology, Clinical Pharmacology and Multidisciplinary Pain Centre, University Hospital, Geneva, Switzerland
    Eur J Anaesthesiol Suppl 28:7-11. 2003
    ..Oral fixed drug combination analgesics have potential advantages over monotherapy, but these can only be attained through careful design...
  5. pmc Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety
    C F Samer
    Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Department of Anaesthesiology, Pharmacology and Intensive Care, Geneva University Hospitals, Geneva, Switzerland
    Br J Pharmacol 160:919-30. 2010
    ..The possible role of an active metabolite in the pharmacodynamics of oxycodone has been questioned and the importance of CYP3A-mediated effects on the pharmacokinetics and pharmacodynamics of oxycodone has been poorly explored...
  6. pmc The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone
    C F Samer
    Clinical Pharmacology and Toxicology and Multidisciplinary Pain Centre, Department of Anaesthesiology, Pharmacology and Intensive Care, Geneva University Hospitals, Switzerland
    Br J Pharmacol 160:907-18. 2010
    ..The effects of CYP2D6 and/or CYP3A activity modulation on the pharmacokinetics of oxycodone remains poorly explored...
  7. doi request reprint Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital
    L Gschwind
    Division of Clinical Pharmacology and Toxicology, University Hospitals of Geneva, Rue Gabrielle Perret Gentil 4, 1211 Geneva 14, Switzerland
    Eur J Clin Pharmacol 69:617-27. 2013
    ..The objective of this study was to identify the most clinically relevant drug-drug interactions (DDIs) at risk of affecting acenocoumarol safety in our tertiary care university hospital, a 2,000 bed institution...
  8. pmc Applications of CYP450 testing in the clinical setting
    C F Samer
    Clinical Pharmacology and Toxicology, Geneva University Hospitals, Rue Gabrielle Perret Gentil 4, 1211, Geneva, Switzerland
    Mol Diagn Ther 17:165-84. 2013
    ..Genotyping and phenotyping may therefore be considered where dosing guidelines according to CYP genotype have been published, and help identify the right molecule for the right patient...
  9. ncbi request reprint Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients
    Y Daali
    Clinical Pharmacology and Toxicology, Geneva University Hospitals, CH 1211 Geneva 14, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 861:56-63. 2008
    ..Finally, this assay was used to determine DEM/DOR molar ratios in fibromyalgia patients for the purpose of determining phenotype status for the CYP2D6...
  10. ncbi request reprint Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability
    V Ancrenaz
    Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, rue Gabrielle Perret Gentil, 1211 Geneva 14, Switzerland
    Curr Drug Metab 11:667-77. 2010
    ..The purpose of this review is to critically examine the current literature evaluating the influence of genetic and environmental factors such as unwanted drug-drug interaction affecting clopidogrel and prasugrel antiplatelet activity...